BiomX Inc. (PHGE-UN)
| Previous close | 0.3711 |
| Open | 0.3720 |
| Bid | 0.2598 x 900 |
| Ask | 0.5201 x 1400 |
| Day's range | 0.3711 - 0.3720 |
| 52-week range | 0.0478 - 0.8200 |
| Volume | |
| Avg. volume | 8,989 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3110 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.00 |
GlobeNewswireBiomX to Present at the 2024 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 06, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the company will participate in the RBC Capital Markets Global Healthcare Conference in New York City on Wednesday, May 15, 2024. Date & Time: Wednesday, May 15, 4:05 PM ETFormat: Presentation and one-on-one meetingsPresenter:
GlobeNewswireBiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present data from the Phase 1b/2a study of BX004 for the treatment of
- GlobeNewswire
BiomX Announces the Appointment of Susan Blum to its Board of Directors
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. “We are pleased to welcome Susan Blum to our Board of Directors who join
